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Abstract
Background: The aim of this study was to evaluate the role of cytokines and soluble adhesion molecules in patients with sud-
den sensorineural hearing loss (SSNHL) with respect to their pure-tone audiometry values.
Material and Methods: This study analyses blood samples of 51 patients with SSNHL. Serum levels of ICAM-1, VCAM-1, 
E-selectin, IL-6, IL-8, and MCP-1 were evaluated by ELISA. Pure-tone audiometry data were compared before and after a sys-
temic steroid treatment regimen. The subjects with SSNHL were compared to a control group of 44 patients with normal hear-
ing and matching age and gender. The data complete our previous data collection.
Results: There is trend toward suppressed levels of MCP-1 in sera of SSNHL patients. There were no statistically significant 
differences concerning ICAM-1, VCAM-1, E-selectin, IL-6, IL-8, and MCP-1 between SSNHL patients and controls. Pure-
tone audiometry of the SSNHL group showed a significant improvement in hearing after systemic steroid therapy and a me-
dian follow-up of 4 months.
Conclusions: Further prospective studies are necessary to prove the role of MCP-1 and other cytokines in SSNHL in order 
to develop adequate treatment regimens.
СОДЕРЖАНИЕ МОНОЦИТАРНОГО ХЕМОАТТРАКТИВНОГО ПРОТЕИНА-1 
ОТЛИЧАЕТСЯ ОТ НОРМЫ У ПАЦИЕНТОВ С ВНЕЗАПНОЙ ПЕРЦЕПТИВНОЙ 
ТУГОУХОСТЬЮ
Резюме
Введение: Целью данного исследования являлась оценка роли цитокинов и растворимых внутриклеточных мо-
лекул у пациентах с внезапной перцептивной тугоухостью (SSNHL) относительно их результатов тональной 
аудиометрии.
Материал и Методы: В данном исследовании рассмотрено образцы крови 51 пациента с SSNHL. Степень содер-
жания ICAM-1, VCAM-1, E-селектина, IL-6, IL-8 и MCP-1 в сыворотке было оценены с помощью энзим-связан-
ного иммуносорбентного анализа (ELISA). Данные тональной аудиометрии были сравнены до и после система-
тического лечения стероидами. Пациенты с SSNHL были сравнены с контрольной группой из 44 пациентов с 
нормальным слухом и соответствующим возрастом и полом. Данные заканчивают наш предыдущий сбор данных.
Результаты: Существует тенденция к меньшему содержанию MCP-1 в сыворотках пациентов с SSNHL. Не выяв-
лено никаких статистически значимых различий относительно ICAM-1, VCAM-1, E-селектина, IL-6, IL-8 и MCP 
1 между пациентами с SSNHL и из контрольной группы. Тональная аудиометрия группы с SSNHL показала су-
щественное улучшение слуха после систематической терапии стероидами и в среднем на протяжении 4 меся-
цев последующей обсервации.
Заключения: Необходимы дополнительные последующие исследования для того, чтобы выявить роль MCP-1 и 
других цитокинов у пациетов с SSNHL для развития соответствующиего лечения.
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Background
Sudden sensorineural hearing loss (SSNHL) is a common 
disorder, but the exact causes of most SSNHL are still un-
known. There are several hypotheses concerning the etiol-
ogy of SSNHL, and an increased blood viscosity [1] in pa-
tients with SSNHL supports a vascular hypothesis. Other 
authors report that SSNHL co-occurring with hyperten-
sion, diabetes mellitus, or dyslipidemias seems to be associ-
ated with a higher prevalence of cerebral microangiopathy 
and with a slower hearing recovery [2]. The consequenc-
es are multiple treatment regimens usually based on ap-
plying steroids orally, intratympanically, or intravenously. 
The high spontaneous recovery rate of SSNHL makes the 
true usefulness of a specific treatment hard to prove [3].
Cytokines [4] and soluble adhesion molecules [5] seem 
to play a major role in inner ear pathologies and in re-
covery processes, which is why this study focused on the 
role of these proteins. Monocyte chemoattractant pro-
tein-1 (MCP-1) has been discussed in several disorders 
in the past: atherosclerosis, diabetes mellitus, angiogene-
sis, and inflammatory tissue reactions seem to be modu-
lated by this chemokine [6].
MCP-1 is a member of the C–C class of the beta chemokine 
family and one of the key factors involved in the initiation 
of inflammation. It triggers chemotaxis and transendothe-
lial migration of monocytes to inflammatory lesions by in-
teracting with the membrane CC chemokine receptor 2 
(CCR2) in monocytes. MCP-1 is secreted by fibroblasts, 
endothelial cells, vascular smooth muscle cells, monocytes, 
T cells, and other cell types[7].
The role of MCP-1 in SSNHL is presently unknown. As 
previously reported [8], we found no statistically signif-
icant differences concerning soluble adhesion molecules 
and cytokines in our study population which included 35 
patients and matching control subjects. The aim of the 
present study was to evaluate the role of these molecules 
in SSNHL pathogenesis by using an increased number of 
blood samples.
Material and Methods
In addition to the 35 patients of our previous work, 16 
more patients affected by a unilateral SSNHL were includ-
ed in this study (n=51). Written consent was obtained for 
the entire study by the Institutional Review Board of the 
University of Regensburg (number 08/120). Inclusion cri-
teria for this study were the same as previously described: 
(1) hearing loss of more than 30 dB HL in more than 3 
contiguous frequencies according to the accepted crite-
ria of the National Institute of Health; (2) age-equivalent 
hearing of the non-affected ear; (3) no history of hearing 
loss or ear surgery in the past. In addition, 9 extra con-
trols and 35 participants from our previous data collec-
tion were included as a control group with matching age 
and sex proportions (n=44); they had no history of hear-
ing loss and age-equivalent hearing according to hearing 
levels of ISO 7029. Pure-tone audiometry and standard 
audiovestibular investigations were obtained for each pa-
tient and control subject as previously described. All SSN-
HL patients received a treatment regimen including intra-
venous infusion of prednisolone, 3% hydroxyethyl starch 
and magnesium for 5 days, followed by oral steroids for 
one more week.
Hearing loss was documented by pure-tone audiometry 
on the first day of the SSNHL diagnosis and 3 to 6 months 
later. The mean hearing loss in the three most affected fre-
quencies was analysed.
At the the first consultation, blood samples were tak-
en before therapy started. Levels of soluble adhe-
sion molecules ICAM-1 (intercellular adhesion mole-
cule 1), VCAM-1 (vascular cell adhesion molecule 1), 
E-selectin (endothelial selectin), and concentrations of 
LOS NIVELES DE PROTEÍNA QUIMIOTÁCTICA DE MONOCITOS 1 DIFERENCIAN 
DE LA NORMA EN PACIENTES CON HIPOACUSIA SENSORINEURAL SÚBITA
Extracto
Introducción: El objetivo de este estudio era evaluar el papel de citocinas y moléculas de adhesión solubles en pacientes con 
hipoacusia sensorineural súbita (SSNHL) con respecto a sus resultados de la audiometría de tonos puros.
Material y Métodos: Este estudio analiza las muestras de sangre de 51 pacientes con SSNHL. Los niveles de ICAM-1, VCAM-
1, E-selectina, IL-6, IL-8 y MCP-1 en suero fueron evaluados por ELISA. Los resultados de la audiometría de tonos puros fue-
ron comparados antes y después de un tratamiento de esteroide sistemático. Los pacientes con SSNHL eran comparados con 
un grupo de control de 44 pacientes con el oído normal y de edad y género correspondiente. Los datos completan nuestra re-
cogida de datos anterior.
Resultados: Existe una tendencia a crecer de los niveles de MCP-1 en sueros de pacientes con SSNHL. No había ningunas dife-
rencias estadísticamente significativas acerca de ICAM-1, VCAM-1, E-selectina, IL-6, IL-8 y MCP-1 entre pacientes con SSNHL 
y de grupo de control. La audiometría de tonos puros del grupo con SSNHL mostró un mejoramiento significativo del oído 
después de la terapia de esteroide sistémica y a continuación de 4 meses.
Conclusiones: Los estudios futuros son necesarios para demostrar el papel de MCP-1 y otros citocines en pacientes con SSNHL 
para desarrollar regímenes de tratamiento adecuados.
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IL-6 (interleukin 6), IL-8 (interleukin 8), and MCP-1 
(monocyte-chemoattractant protein 1) were measured 
using established enzyme-linked-immunosorbent as-
says (R&D Systems QUANTAKINE, Human sVCAM-1 
Immunoassay, Human sICAM-1/CD54 Immunoas-
say, Human sE-Selectin/CD62E Immunoassay, Human 
CCL2/MCP-1 Immunoassay, Siemens IMMULITE 2000 
IL-6, DPC IMMULITE IL-8) according to the manufac-
turer’s instructions.
Statistical analysis was performed with SPSS 18.0 for Win-
dows (SPSS Inc., Chicago, USA). Statistical significance 
was set at p<0.05.
Results
A total number of 51 patients with SSNHL were included in 
the study and compared to 44 subjects with normal hearing.
The median age in the patient group was 56 years (22–87 
years) and there were 32 males and 19 females. The me-
dian age in the control group was 48 years (18–68 years) 
including 29 males and 15 females. There were no sta-
tistically significant (p>0.05) differences in age or gen-
der between the groups. Risk factors such as diabetes, 
hypertension, and smoking habits were similar in both 
groups. Exactly 26 SSNHL patients agreed to a control 
examination and were re-evaluated by pure-tone audi-
ometry after a follow-up of more than 3 months. The 
mean hearing loss in the three most affected frequen-
cies was analysed. There was a statistically significant 
(p<0.001) improvement of hearing in the follow-up ex-
amination (Figure 1).
As already documented in our previous analysis of 35 
patients and controls [8], the levels of soluble intercellu-
lar adhesion molecule-1, soluble vascular cell adhesion 
molecule-1, endothelial selectin, and MCP-1 in sera of 
SSNHL patients (Figure 2) were not significantly differ-
ent from those of the control group. However, there was 
an obvious difference in the number of subjects present-
ing with suppressed MCP-1 values in the SSNHL group 
compared to the control group. With respect to the nor-
mal range, there were more SSNHL patients with sup-
pressed levels of MCP-1 than the controls (Figure 3). 
This difference was highly significant in the chi-square 
test (p<0.001). The normal range of the MCP-1 assay was 
determined on the basis of 37 samples from apparently 
healthy volunteers according to information of the man-
ufacturer (Human CCL2/MCP-1 Immunoassay; QUAN-
TAKINE, R&D Systems, Minneapolis, USA). The similar 
normal range values were published in a study of Take-
bayashi et al. [9].
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Figure 3.  Absolute number of SSNHL patients and control 
subjects with MCP-1 serum levels within and 
under the normal range of the present assay 
(200–722 pg/mL).
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Figure 1.  Box plots of mean average hearing loss before 
(MHL 1) and after (MHL 2) treatment in the fol-
low-up examination. MHL 1 is calculated as the 
mean hearing loss in the three most affected 
frequencies. MHL 2 represents the mean val-
ues of the same frequencies in the follow-up. 
Box plots include median, 25%/75% percen-
tile (boxes), and minimum/maximum values 
(whiskers).
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Figure 2.  Box plots of serum MCP-1 levels in control sub-
jects and SSNHL patients. Box plots include 
median, 25%/75% percentile (boxes), and min-
imum/maximum values (whiskers).
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The additional recruitment of 16 patients and 9 controls 
did not result in a statistically significant difference con-
cerning the analysed cytokines IL-6 and IL-8.
Discussion
It is assumed that microcirculation disturbances condi-
tioned by an endothelial dysfunction might represent an 
important cause for the development of SSNHL. Adhesion 
molecules favoring interaction between leukocytes and 
endothelial cells are early markers of endothelial damage. 
The sudden onset and the fact that the inner ear vascu-
larisation is provided by a functional end artery might be 
an indication of similar vascular pathogenesis in SSNHL 
and cardiovascular disease. In contrast to Quaranta et al. 
[5], who analysed 37 SSNHL patients, VCAM-1 was not 
significantly higher in our group of 51 SSNHL patients.
Our present study (including the previous data collection 
[8]) does not support the hypothesis that endothelial dys-
function might be involved in the etiology of SSNHL. We 
could not document elevated levels of soluble adhesion 
molecules in SSNHL patients as compared to a control 
group of subjects with normal hearing.
Cytokines such as IL-6, IL-8, and MCP-1 are involved in 
leukocyte adherence and favour cellular extravasation into 
inflamed tissue [10]. Inflammatory cytokines play critical 
roles in a variety of cellular processes. Knowledge about 
the identity and cellular localisation of these compounds 
within the ear is sparse. MCP-1 also seems to be involved 
in inner ear pathologies [11,12]. Whether this molecule 
takes part in SSNHL pathogenesis is still unknown. We can 
see a trend toward different levels of MCP-1 in the SSN-
HL group. With respect to the accepted normal range, we 
found more levels under the estimated value of 200 pg/
mL. One control and 7 patients were not included in this 
analysis because of MCP-1 levels below the detection limit 
of our assay. This fact may support our hypothesis of sup-
pressed MCP-1 levels in patients with SSNHL.
The intake of antihypertensive drugs and comorbidities 
such as diabetes mellitus can influence MCP-1 serum lev-
els [13,14], but there was no association between medica-
tion or comorbidities and this effect in our study. Bianchi 
et al. [15] report the first observation of the chemokine 
MCP-1 as an inner-ear-derived, neurite-promoting mol-
ecule. In a cell culture model they describe MCP-1 as the 
growth factor for outgrowth from the statoacoustic gan-
glion. With respect to the idea of MCP-1 as a nerve-pro-
moting factor in the inner ear, the deficient spontaneous 
recovery of patients suffering from SSNHL might be ex-
plained by their suppressed serum levels of this cytokine.
While this observation may help our understanding, the 
pathology of SSNHL is still unclear and further research 
concerning the role of MCP-1 in SSNHL is needed. With 
more research, the roles of MCP-1 in various clinical con-
ditions (e.g. diabetes mellitus, atherosclerosis, infection 
and inflammation) will continue to be elucidated. How-
ever, the critical question that still needs to be addressed 
is whether chemokine expression is pathogenetically re-
sponsible for any of the manifestations of these diseases. 
This has been very difficult to address in humans because 
of the apparent absence of genetic abnormalities involv-
ing chemokines and their receptors [6].
The deficient understanding of SSNHL might be one rea-
son for the variety of therapeutic regimens. The SSNHL pa-
tients in our study were treated with hydroxyethyl starch, 
intravenously administered corticosteroids, and magnesi-
um. A significant improvement of hearing was observed 
in the re-examination of 26 patients after a median fol-
low-up of 4 months. Usually there is no further improve-
ment in hearing 2 weeks after an event of SSNHL [16]. The 
relatively low rate of patients in the control examination 
is due to the fact that many of the patients live far away 
from our institution. There are little data concerning the 
evidence of magnesium and other mineral supplements 
in SSNHL, but also other authors recommend magnesi-
um substitution [17]. A recent systematic literature review 
concluded that a direct causal link between SSNHL and 
previously discussed etiologies remains elusive [18]. That 
is why further investigations and consideration of differ-
ent factors such as growth factors are necessary.
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